Zymeworks Inc.ZYMENASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

globenewswire.com

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Citi's 2026 Virtual Oncology Leadership Summit: Zymeworks' management will participate in one-on-one meetings February 18-19, 2026 virtually. TD Cowen 46th Annual Health Care Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on March 2, 2026 at 14:30 pm – 15:00 pm Eastern Time (ET) in Boston, MA.

defenseworld.net

Mark Hollywood Sells 6,120 Shares of Zymeworks (NYSE:ZYME) Stock

Zymeworks Inc. (NYSE: ZYME - Get Free Report) COO Mark Hollywood sold 6,120 shares of the company's stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $138,740.40. Following the completion of the sale, the chief operating officer directly owned 132,913

seekingalpha.com

Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

globenewswire.com

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intended to strengthen the capabilities and experience of the organization. These updates are designed to align key leadership roles with the Company's corporate strategy announced in November.

seekingalpha.com

HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth

Zymeworks delivered strong Phase 3 HERIZON-GEA-01 results for Ziihera, achieving over two years median overall survival in HER2-positive GEA. ZYME stands to receive up to $440 million in milestone payments upon regulatory approvals, dwarfing its recent $27.6 million quarterly revenue. Ziihera's efficacy was consistent across PD-L1 subgroups, with manageable safety, positioning it as a potential new first-line standard for HER2-positive GEA.

globenewswire.com

Zymeworks Outlines Strategic Priorities and Outlook for 2026

VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significant clinical, operational and financial progress, Zymeworks is focused on executing a long-term strategy designed to maximize value creation for patients, partners, and shareholders.

feeds.benzinga.com

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Jazz Pharmaceuticals reported Phase 3 trial results showing Ziihera helped patients with advanced HER2-positive stomach cancer live longer, with some treatments pushing survival beyond two years.

defenseworld.net

Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of “Buy” from Analysts

Zymeworks Inc. (NYSE: ZYME - Get Free Report) has been given a consensus recommendation of "Buy" by the eleven ratings firms that are covering the firm, Marketbeat.com reports. Eleven research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in the

globenewswire.com

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

VANCOUVER, British Columbia, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction and esophagus.

defenseworld.net

Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 20,110 Shares of Stock

Zymeworks Inc. (NYSE: ZYME - Get Free Report) insider Paul Andrew Moore sold 20,110 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $25.10, for a total value of $504,761.00. Following the transaction, the insider owned 31,212 shares of the company's stock, valued at

defenseworld.net

Zymeworks (NYSE:ZYME) EVP Jeffrey Smith Sells 10,538 Shares

Zymeworks Inc. (NYSE: ZYME - Get Free Report) EVP Jeffrey Smith sold 10,538 shares of the company's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $25.10, for a total transaction of $264,503.80. Following the completion of the transaction, the executive vice president owned 18,352 shares of the

defenseworld.net

Zymeworks Inc. $ZYME Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. raised its stake in Zymeworks Inc. (NYSE: ZYME) by 169.2% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,326,774 shares of the company's stock after buying an additional 833,994 shares during the quarter. Assenagon Asset Management S.A. owned approximately 1.77% of

defenseworld.net

Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Buy” from Brokerages

Shares of Zymeworks Inc. (NYSE: ZYME - Get Free Report) have earned an average recommendation of "Buy" from the ten brokerages that are covering the stock, Marketbeat reports. Ten investment analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have updated their coverage on the stock in the

seekingalpha.com

Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

globenewswire.com

Zymeworks Announces Participation in Upcoming Conferences

• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera ® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI • Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT) VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced participation in the following upcoming conferences.

defenseworld.net

Critical Review: Acerus Pharmaceuticals (OTCMKTS:ASPCF) vs. Zymeworks (NASDAQ:ZYME)

Acerus Pharmaceuticals (OTCMKTS:ASPCF - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Valuation and Earnings This table compares Acerus Pharmaceuticals

globenewswire.com

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Evercore 8th Annual Healthcare Conference in Miami: Zymeworks' management will participate in one-on-one meetings and a fireside chat on December 2, 2025, at 10:00 am Eastern Time (ET) in Miami, FL. Citi 2025 Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on December 3, 2025 at 3:15 pm ET in Miami, FL.

seekingalpha.com

Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA

Zymeworks is gaining momentum as Ziihera shows strong Phase III data in HER2+ gastroesophageal adenocarcinoma, supporting growth and de-risking the investment. ZYME's royalty-based business model with partners like Jazz and BeOne enables pipeline focus while targeting blockbuster potential, with peak sales estimates exceeding $2B for Ziihera. Risks remain, including regulatory uncertainties and competition from ENHERTU, but ZYME's solid cash position and clinical progress support a 3/5 conviction rating.

seekingalpha.com

Zymeworks: A Lot Of Moving Parts

This article revisits Zymeworks Inc. following significant new trial data released this week. This triggered a 30% rally in ZYME stock on Monday, even as most of any future revenues will accrue to partners Jazz Pharmaceuticals and BeOne. Zymeworks does have a solid balance sheet, several additional partnerships with major drug concerns, and multiple other ADCs in development.

seekingalpha.com

Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript

Zymeworks Inc. ( ZYME ) Shareholder/Analyst Call November 18, 2025 8:30 AM EST Company Participants Shrinal Inamdar - Director of Investor Relations Kenneth Galbraith - Chairman of the Board, CEO & President Conference Call Participants Seung Won Paik - LifeSci Capital, LLC, Research Division Andrew Berens - Leerink Partners LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Joohwan Kim Jonathan Miller - Evercore ISI Institutional Equities, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Yaron Werber - TD Cowen, Research Division Eva Fortea-Verdejo - Wells Fargo Securities, LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Presentation Operator Thank you for standing by, and welcome to Zymeworks Strategy Update Conference Call and Webcast.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance